



1 Membership

- 1.1 All Committee members should be independent Non-Executive Directors. As far as is practical, one Committee member will also be a member of the Audit & Risk Committee (“ARC”).

2 Attendance at Meetings

- 2.1 Only members of the Committee have the right to attend Committee meetings. However, the following Senior Executives shall be invited to attend for all or part of the Committee’s meetings as required:

- i) Chief Executive Officer
- ii) Chief Financial Officer
- iii) Chief Scientific Officer
- iv) SVP and General Counsel
- v) President, Global Affairs
- vi) VP, Responsible Business and Reputation
- vii) Chief People Officer
- viii) Chief Commercial Officer
- ix) President, Global Supply Chain
- x) CEO ViiV Healthcare and President, Global Health, GSK

Other Executives may be invited to attend the Committee as necessary.

3 Frequency of Meetings

- 3.1 The Committee shall meet four times a year or more frequently if necessary to consider specific issues.

4 Duties

- 4.1 The Committee shall:

- 4.1.1 review the Company’s policies and practices in anticipating and managing external issues that have the potential to seriously impact upon the Company’s business and reputation. This will include consideration and oversight of the Company’s Trust priority and progress reports on the Company’s Responsible Business approach and performance (including the Responsible Business Performance Rating) which reflect important issues for responsible and sustainable long-term business growth. The key areas of focus for the Committee are:

- i) Access;
- ii) Environment;
- iii) Global health and health security;
- iv) Inclusion and diversity
- v) Product governance; and
- vi) Ethical standards, including human rights.

- 4.1.2 review the progress on commitments and goals and targets set out in the Company’s annual reporting and how these will be pursued going forward.

- 4.1.3 shall decide which issues come within its discretion to review. The outcome of such reviews will be presented to the Board either directly or via the Risk & Oversight Compliance Council and the Audit



& Risk Committee if significant risks (including reputational risks) to the Company's business are identified.

- 4.1.4 oversee the Enterprise Risks determined by the Board to be most relevant to the Committee's area of expertise and responsibility and in this regard, the Committee will receive relevant materials and advice in relation to these risks including highlights from relevant Audit & Assurance and Compliance outcomes, as appropriate.

As at 28 January 2025, these risks are:

- i) Supply Continuity
- ii) Product Quality

- 4.1.5 oversee and recommend approval to the Board of the Company's Responsible Business, Modern Slavery Statement and Gender Pay Gap disclosures.